8531.5000 25.00 (0.29%)
NSE Apr 20, 2026 15:31 PM
Volume: 4,673
 

8531.50
0.29%
AstraZeneca covid-19 antibody treatment suffers setback
livemint
Drug's efficacy as post-infection therapy falls short in clinical trial, but potential preventative use is still undergoing testing
More from AstraZeneca Pharma India Ltd.
Recommended